Results 91 to 100 of about 11,915,644 (318)

Immune Trait Polygenic Scores Among Survivors of Hodgkin Lymphoma

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Epidemiologic evidence links immune‐related conditions to Hodgkin lymphoma (HL), but the shared genetic architecture remains unclear. Using data from the St. Jude Survivorship Portal, pre‐computed polygenic risk scores (PRSs) for 12 allergy and immune‐related traits were compared between 794 survivors of HL and 3664 survivors of non ...
Ji Yun Tark   +3 more
wiley   +1 more source

Salmonella Breaks Tumor Immune Tolerance by Downregulating Tumor Programmed Death-Ligand 1 Expression

open access: yes, 2019
Immunotherapy is becoming a popular treatment modality in combat against cancer, one of the world’s leading health problems. While tumor cells influence host immunity via expressing immune inhibitory signaling proteins, some bacteria possess ...
Che-Hsin Lee   +2 more
core   +1 more source

Engineering the tumor microenvironment of colorectal cancer [PDF]

open access: yes, 2014
The tumor microenvironment contributes significantly to the clinical prognosis, especially in CRC. Infiltration by cells from the adaptive immune system (e.g. CD8) has been linked to a better survival independently of TNM-stage.
Hirt, Christian Kurt
core   +1 more source

Multi-omics reveals CXCR4 drives immune escape in colorectal cancer via metabolic reprogramming and immune microenvironment remodeling

open access: yesCell Death and Disease
Colorectal cancer (CRC) is one of the most common malignant tumors with the highest incidence and mortality rates worldwide. Immune checkpoint blockade (ICB) therapy has revolutionized the landscape of cancer treatment; however, most patients with CRC ...
Chengle Zhu   +12 more
doaj   +1 more source

Investigating transcription factor dynamics in health and disease using FRAP

open access: yesFEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj   +3 more
wiley   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

open access: yesFEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta   +3 more
wiley   +1 more source

Tumor microenvironment in treatment of glioma

open access: yesOpen Medicine, 2017
AbstractGlioma is one of the most malignant and fatal tumors in adults. Researchers and physicians endeavor to improve clinical efficacy towards it but made little achievement. In recent years, people have made advances in understanding characteristics and functions of tumor microenvironment and its role in different processes of tumor.
Li Guijie   +5 more
openaire   +3 more sources

Identification of tumor-specific Salmonella Typhimurium promoters and their regulatory logic [PDF]

open access: yes, 2011
Conventional cancer therapies are often limited in effectiveness and exhibit strong side effects. Therefore, alternative therapeutic strategies are demanded.
Igor V. Deyneko   +16 more
core   +1 more source

Structure‐forward targeting of claudins with synthetic binders

open access: yesFEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma [PDF]

open access: yes, 2008
Background: Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths. Difficulties to diagnose HCC at early stages remain the major obstacle to curative (surgical) therapy. Therapy in advanced stages has to be considered palliative.
Forstpointner, Roswitha   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy